Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Neurocrine (NBIX – Research Report), with a price ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a ...

Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

Discover the latest advancements in gene therapy for rare diseases like Friedreich's Ataxia and Duchenne Muscular Dystrophy, ...

Bain Capital is in talks to acquire Mitsubishi Chemical Group's pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a transaction that could ...

In the tough market conditions last year, investors and big pharma companies were more likely to place their bets on later, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.